文献速递脑血管病认知障碍与痴呆

伴皮质下梗死和白质脑病的常染色体显性遗传性脑动脉病(CADASIL)等NOTCH3相关小血管病的疾病严重程度分期系统

Disease Severity Staging System for NOTCH3-Associated Small Vessel Disease, Including CADASIL.
PubMed 文献 · JAMA Neurol · 2025-01-01

该队列研究利用发现队列(2019-2020年)和国际CADASIL队列(1999-2023年)及英国生物银行数据,开发并验证了涵盖9个疾病分期的NOTCH3相关小血管病严重程度分期系统。在1908例NOTCH3cys阳性病例中,1789例(94%)遵循该分期系统定义的事件顺序,分期与神经影像、认知结局、血清NfL水平及18年生存相关。

要点

  • NOTCH3cys变异携带者表型谱广泛,从早发卒中痴呆(CADASIL)到无外显。
  • NOTCH3-SVD分期系统包含9个疾病分期或亚期,从0期(症状前)到4B期(终末期)。
  • 该分期系统在CADASIL队列和英国生物银行中与神经影像结局相关,在CADASIL队列中与认知结局和血清NfL水平相关。

核心结论

  • NOTCH3-SVD分期系统涵盖从无症状NOTCH3cys变异携带者到终末期患者的完整疾病谱。
  • NOTCH3-SVD分期系统是临床上和研究中用于统一疾病分期的简单而有效的工具。

研究设计与样本

  • 队列研究,使用发现队列(2019-2020年)开发NOTCH3-SVD严重程度分期系统,并在独立国际CADASIL队列(1999-2023年)和英国生物银行中验证。
  • 临床和影像数据来自23个国际CADASIL队列和英国生物银行,纳入标准为存在NOTCH3cys变异、有脑磁共振成像和改良Rankin量表评分。
  • 发现队列为195例来自CADASIL家系的NOTCH3cys阳性病例;验证集包括来自15个国家的1713例NOTCH3cys阳性病例;英国生物银行队列包括101例NOTCH3cys阳性个体。
  • 还分析了2年(2019-2023年)和18年(1999-2017年)随访研究的数据;数据分析于2023年7月至2024年8月进行。

主要发现

  • NOTCH3-SVD分期系统包含9个疾病分期或亚期,从0期(症状前阶段)到4B期(终末期)。
  • 全部1908例病例中,1789例(94%)遵循NOTCH3-SVD分期系统定义的事件顺序;发现队列195例(平均[SD]年龄52.4[12.2]岁),验证队列1713例(平均[SD]年龄53.1[13.0]岁)。
  • NOTCH3-SVD分期与CADASIL队列和英国生物银行中NOTCH3cys阳性病例的神经影像结局相关,并与CADASIL队列病例的认知结局和血清NfL水平相关。
  • NOTCH3-SVD分期系统捕捉了疾病进展,并与18年生存相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Typical cysteine-altering NOTCH3 (NOTCH3cys) variants are highly prevalent (approximately 1 in 300 individuals) and are associated with a broad spectrum of small vessel disease (SVD), ranging from early-onset stroke and dementia (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy [CADASIL]) to nonpenetrance. A staging system that captures the full NOTCH3-SVD severity spectrum is needed and currently lacking. OBJECTIVE: To design a simple disease severity staging system that captures the broad clinicoradiological NOTCH3-SVD severity spectrum. DESIGN, SETTING, AND PARTICIPANTS: A cohort study was performed in which the NOTCH3-SVD severity staging system was developed using a discovery cohort (2019-2020) and validated in independent international CADASIL cohorts (1999-2023) and the UK Biobank. Clinical and imaging data were collected from participants originating from 23 international CADASIL cohorts and from the UK Biobank. Eligibility criteria were presence of a NOTCH3cys variant, availability of brain magnetic resonance imaging, and modified Rankin Scale score. The discovery cohort consisted of 195 NOTCH3cys-positive cases from families with CADASIL; the validation set included 1713 NOTCH3cys-positive cases from 15 countries. The UK Biobank cohort consisted of 101 NOTCH3cys-positive individuals. Data from 2-year (2019-2023) and 18-year (1999-2017) follow-up studies were also analyzed. Data analysis was performed from July 2023 to August 2024. MAIN OUTCOMES AND MEASURES: Percentage of cases following the sequence of events of the NOTCH3-SVD stages, and the association between the stages and ischemic stroke, intracerebral hemorrhage, global cognition, processing speed, brain volume, brain microstructural damage, and serum neurofilament light chain (NfL) level. RESULTS: The NOTCH3-SVD staging system encompasses 9 disease stages or substages, ranging from stage 0 (premanifest stage) to stage 4B (end stage). Of all 1908 cases, which included 195 in the discovery cohort (mean [SD] age, 52.4 [12.2] years) and 1713 in the validation cohorts (mean [SD] age, 53.1 [13.0] years), 1789 (94%) followed the sequence of events defined by the NOTCH3-SVD staging system. The NOTCH3-SVD stages were associated with neuroimaging outcomes in the NOTCH3cys-positive cases in the CADASIL cohorts and in the UK Biobank and with cognitive outcomes and serum NfL level in cases from the CADASIL cohorts. The NOTCH3-SVD staging system captured disease progression and was associated with 18-year survival. CONCLUSIONS AND RELEVANCE: The NOTCH3-SVD staging system captures the full disease spectrum, from asymptomatic individuals with a NOTCH3cys variant to patients with end-stage disease. The NOTCH3-SVD staging system is a simple but effective tool for uniform disease staging in the clinic and in research.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Gravesteijn G, Rutten JW, Cerfontaine MN, et al. Disease Severity Staging System for NOTCH3-Associated Small Vessel Disease, Including CADASIL. JAMA Neurol. 2025. PMID: 39610302. doi:10.1001/jamaneurol.2024.4487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。